Identification of dephosphorylation related genes prognostic signature in cervical squamous cell carcinoma and endocervical adenocarcinoma - Observational Study

Sep 23, 2026

Protein phosphorylation and dephosphorylation regulate eukaryotic metabolism and cancer progression, yet the prognostic and predictive value of dephosphorylation-related genes in cervical squamous cell carcinoma and endocervical adenocarcinoma (CESC) remains insufficiently characterized. Using TCGA gene expression and clinical data, a prognostic signature was built with LASSO regression and multivariate Cox analysis, then assessed by Kaplan–Meier and ROC curves. Six genes formed the model, showing strong performance (ROC-AUC 0.802).

LanguageEnglish

CategoryHealthcare

FormatPDF

Pages8

Reading Time20 min

AccessFree to download

Abstract

Abbreviations and Keywords

Introduction

Patient background and clinical need

Rationale for dephosphorylation-related biomarkers

Methods and Results Overview

Gene selection and model construction

Survival and predictive evaluation

Genetic alteration analysis

Conclusion and Clinical Implication

Figures and Tables

® Observational Study Identification of dephosphorylation related genes prognostic signature in cervical squamous cell carcinoma and endocervical adenocarcinoma Jinwei Li, MSa , Xiaoyan Zhong, MSa , Yao Mou, MSa , Xuemei Tao, MSa , Yating Tang, BSb , Longyang Jiang, PhDa ,b ,* | Abstract
Protein phosphorylation and dephosphorylation play critical regulatory roles in eukaryotic cell metabolism and cancer progression. Although phosphatase-mediated dephosphorylation has been shown to influence multiple signaling pathways in cervical cancer, the prognostic and predictive value of phosphorylation/dephosphorylation-related genes in cervical squamous cell carcinoma and endocervical adenocarcinoma (CESC) has remained poorly explored. This study aimed to develop and validate a prognostic signature of CESC based on dephosphorylation-related genes. Gene expression data and clinical characteristics of patients with CESC were obtained from The Cancer Genome Atlas database. A prognostic signature was constructed using least absolute shrinkage and selection operator regression and multivariate Cox regression analyses. Kaplan–Meier survival analysis and receiver operating characteristic curves were used to evaluate the predictive performance of the signature. Six genes were selected to construct a prognostic signature from a pool of 425 dephosphorylation-related genes. Genetic alteration analysis of 291 CESC patients, conducted using the cBioPortal database, revealed that 278 (95 .5%) patients harbored alterations in at least one of these 6 genes. Among 278 patients, a total of 28 mutations were detected across 6 genes. The prognostic signature demonstrated strong predictive power, with an area under the receiver operating characteristic curve of 0.802. A 6-gene dephosphorylationrelated prognostic signature was successfully developed and validated as an independent predictor of overall survival in patients with CESC. This signature may aid clinicians in the early identification of high-risk patients and in guiding personalized treatment strategies. | | --- | | Abbreviations: AUC = area under curve, CESC = cervical squamous cell carcinoma and endocervical adenocarcinoma, OS = overall survival, ROC-AUC = area under the receiver operating characteristic curve, TCGA = The Cancer Genome Atlas. | | Keywords: biomarkers, cervical squamous cell carcinoma and endocervical adenocarcinoma, CESC, , dephosphorylation, prognostic indicator, tumorigenesis | 1. Introduction Cervical squamous cell carcinoma and endocervical adenocarcinoma (CESC) are the most common malignancy of cervical cancer. Cervical cancer is one of the most common cancers and the 4th leading cause of cancer-related deaths in women.[1] In 2020, it was estimated that there would be 604,000 new cases and 342,000 deaths worldwide.[1] Similarly, cervical cancer is the second leading cause of cancer mortality among women aged 20 to 39 years in the United States.[2] The American Cancer Society recommends cervical cancer screening every 5 years in women starting at the age of 25.[3] Cervical cancer screening and HPV vaccination can effectively reduce the incidence of cervical cancer and cancer-related death. However, the prognosis of cervical cancer is poor, particularly in patients with advanced cervical cancer. The 5-year survival rate is 15% .[4] Therefore, it is necessary to explore new biomarkers for early diagnosis and prognosis of cervical cancer. Previous studies have revealed that protein phosphorylation/ dephosphorylation plays a key role in regulating complex biological systems, such as signal transduction, cell growth, protein synthesis, and disease processes, including metabolic diseases, autoimmune diseases, cancer, neurodevelopmental disorders.[5,6] Protein phosphorylation/dephosphorylation has an important influence on the function and properties of proteins, and can This study was supported by the Doctoral Research Initiation Fund of the Affiliated Hospit

FAQs

What is the purpose of this study in CESC patients?

To develop and validate a prognostic signature based on dephosphorylation-related genes for cervical squamous cell carcinoma and endocervical adenocarcinoma.

How was the prognostic signature constructed and evaluated?

Gene expression and clinical data from TCGA were analyzed using LASSO regression and multivariate Cox regression, then assessed with Kaplan–Meier survival analysis and ROC curves.

How many genes were included in the final signature, and how accurate was it?

The signature used six genes selected from 425 dephosphorylation-related genes and demonstrated ROC-AUC performance of 0.802.

Sep 23, 2026

Uploaded by Lucas Martin